OLAPLEX HOLDINGS (OLPX)

• Olaplex reported Q3 2025 net sales of $114.6 million, a 3.8% decrease year-over-year, which outperformed expectations.
• Adjusted EBITDA for Q3 2025 was $30.8 million, representing a 26.9% margin, also exceeding internal expectations.
• The company reaffirmed its full year 2025 guidance, expecting net sales in the range of -3% to +2% versus fiscal year 2024, an adjusted gross margin between 70.5%-71.5%, and an adjusted EBITDA margin of 20%-22%.
• Strategic progress included the successful late August launch of two new hair masks, which contributed to improved sell-through trends, and the acquisition of Provalus Bioscience to bolster future innovation.

• OLPX reported Q3 2025 net sales of $114.6 million, representing a 3.8% decrease compared to Q3 2024, with Adjusted EBITDA declining to $30.8 million from $44.6 million in the prior year period.
• Net income for Q3 2025 was $11.1 million, down from $14.8 million in Q3 2024, while diluted EPS remained flat at $0.02.
• The company provided fiscal year 2025 guidance, projecting net sales between $410 million and $431 million and an Adjusted EBITDA Margin of 20% to 22%.
• OLPX completed the acquisition of Purvala Bioscience, Inc. on August 20, 2025.
• Long-term debt was significantly reduced to $352.1 million as of September 30, 2025, from $643.7 million on December 31, 2024.

• OLAPLEX Holdings, Inc. reported a 3.8% decrease in net sales to $114.6 million for the third quarter ended September 30, 2025, with net income of $11.1 million and diluted EPS of $0.02.
• For the nine months ended September 30, 2025, net sales were $317.8 million, and net income was $3.85 million, resulting in diluted EPS of $0.01.
• The company reaffirmed its fiscal year 2025 guidance, expecting net sales between $410 million and $431 million, an adjusted gross profit margin of 70.5% to 71.5%, and an adjusted EBITDA margin of 20% to 22%.
• As of September 30, 2025, cash and cash equivalents were $286.4 million, and long-term debt, net, was $352.1 million.

• Olaplex Holdings, Inc. reported a 3.8% decrease in net sales to $114.6 million for the third quarter of 2025 compared to the prior year period. This decline was primarily driven by a 13.5% decrease in Specialty Retail and a 2.9% decrease in Direct-To-Consumer sales, partially offset by a 5.3% increase in Professional sales.
• Net income for Q3 2025 was $11.1 million, down from $14.8 million in Q3 2024, with diluted EPS remaining flat at $0.02. For the nine months ended September 30, 2025, net income was $3.850 million and diluted EPS was $0.01, a significant decrease from $28.322 million and $0.04 respectively in the prior year period.
• The company reaffirmed its fiscal year 2025 guidance, projecting net sales between $410 million and $431 million, an adjusted gross profit margin of 70.5% to 71.5%, and an adjusted EBITDA margin of 20% to 22%.
• As of September 30, 2025, cash and cash equivalents totaled $286.4 million, a decrease from $586.0 million at December 31, 2024. Long-term debt, net, was reduced to $352.1 million from $643.7 million over the same period.

• Olaplex Holdings is executing a multi-pronged transformation strategy in FY 2025, focusing on expanding its market beyond damage repair, strengthening professional partnerships, and enhancing brand marketing, with year-to-date sales flat and sequential sell-through improvements.
• For the first half of FY 2025, net sales were $203 million, approximately flat year over year, with an adjusted EBITDA margin of 24.7%.
• The company maintained its FY 2025 guidance, projecting net sales in the range of -3% to +2% versus FY 2024, adjusted gross margin between 70.5% and 71.5%, and adjusted EBITDA margins of 20% to 22%.
• Olaplex paid down $300 million of debt in April 2025, saving an estimated $20 million in annual interest , and expects Q3 2025 net sales to decline by high single digits year over year, followed by strong high single-digit growth in Q4 2025.
• Recent product launches in H1 2025 include the Scalp Longevity Treatment and No. 4 and No. 5 Fine wash care system, and the company recently acquired Provala Bioscience.

• Olaplex Holdings has completed its first-ever acquisition by purchasing Purvala Bioscience, a Boston-based biotech firm founded in 2020 by Drs. Bradley Olsen and Justin Paloni.
• Purvala Bioscience specializes in developing bioinspired molecules for the health and beauty sectors, and this acquisition aims to enhance Olaplex's product portfolio with new science-backed beauty solutions alongside its patented Bis-amino technology.

Olaplex's financial performance for the trailing twelve-month period is as follows: